1. CASE PRESENTATION
====================

Upon abdominal computed tomography ([ct]{.smallcaps}) imaging performed to rule out nephrolithiasis, a 57-year-old woman was incidentally found to have a 5-cm renal mass. The patient subsequently underwent a right-sided nephrectomy, and pathology analysis of the surgical specimen revealed a 5-cm Fuhrman grade 2 clear-cell-type renal cell carcinoma. Imaging by [ct]{.smallcaps} of the chest, abdomen, and pelvis at that time showed no evidence of distant disease, and the patient was followed clinically by her urologist.

Roughly 2 years later, the patient presented to her primary care practitioner with vague complaints of fatigue and lethargy. Initial workup included a complete blood count, remarkable for a pronounced leucocytosis (30,000 white cells/μL, normal differential). Subsequent bone marrow examination was consistent with a diagnosis of chronic myelogenous leukemia ([cml]{.smallcaps}), and the patient was initiated on therapy with imatinib. The patient tolerated therapy with minimal adverse effects, and within 3 months of therapy initiation, she had mounted a complete cytogenetic response by peripheral blood Bcr--Abl mutation screening.

The patient continued to demonstrate a durable remission on imatinib therapy. However, at a time corresponding to roughly 4 years of imatinib therapy, the patient was noted to have onset of cough and shortness of breath. Imaging of the chest by [ct]{.smallcaps} revealed multiple pulmonary nodules, and [ct]{.smallcaps}-guided biopsy of a representative lesion was consistent with clear-cell carcinoma of the kidney. After a discussion of potential therapeutic options, the patient was initiated on therapy with bevacizumab while continuing treatment with imatinib.

Six months after initiation of the bevacizumab therapy, interval imaging data shows no significant change ([Figure 1](#f1-co16-2-44){ref-type="fig"}), and the patient has experienced no toxicities related to either therapeutic agent.

2. DISCUSSION
=============

2.1 Targeted Therapy for mRCC and CML
-------------------------------------

Chronic myelogenous leukemia and metastatic renal cell carcinoma (m[rcc]{.smallcaps}) represent two disorders whose therapies have been revolutionized by the advent of targeted agents. The natural history of [cml]{.smallcaps} has been drastically altered by the Bcr--Abl tyrosine kinase inhibitor ([tki]{.smallcaps}) imatinib. Use of imatinib has been validated with 5-year follow-up data from a study of 1106 patients randomized to either imatinib or interferon alfa plus cytarabine. In that study, a complete cytogenetic response was obtained in 69% of patients by 12 months and in 87% of patients by 60 months[@b1-co16-2-44].

Although imatinib provides a durable remission, patients refractory to the drug also have therapeutic alternatives such as dasatinib or nilotinib. Dasatinib, a Bcr--Abl [tki]{.smallcaps} that targets most imatinib-resistant *BCR--ABL* mutations, was shown to cause a complete hematologic response in 93% of patients assessed with chronic-phase [cml]{.smallcaps}, and a major hematologic response in 70% of patients with accelerated-phase disease [@b2-co16-2-44]. A similar study to assess the activity of nilotinib also yielded data suggesting activity of this novel [tki]{.smallcaps} in the setting of imatinib-resistant [cml]{.smallcaps}[@b3-co16-2-44].

Emerging data also suggest the utility of a targeted approach to the treatment of m[rcc]{.smallcaps}. Based on results of a meta-analysis assessing six prospective trials, interferon alfa had previously been accepted as the standard treatment for m[rcc]{.smallcaps}. A total of 463 patients with m[rcc]{.smallcaps} had received therapy with interferon alfa, yielding a median time to progression of 4.7 months and a median overall survival ([os]{.smallcaps}) of 13.1 months[@b4-co16-2-44]. Those data led to the use of interferon alfa as a comparator in the phase [iii]{.smallcaps} trial of sunitinib, an oral [tki]{.smallcaps} targeting the vascular endothelial growth factor receptor ([vegfr]{.smallcaps}) and platelet-derived growth factor receptor ([pdgfr]{.smallcaps})[@b5-co16-2-44]. In 750 patients with previously untreated clear-cell m[rcc]{.smallcaps}, an improvement in progression free survival ([pfs]{.smallcaps}) was observed with sunitinib \[10.9 months vs. 5.1 months; hazard ratio ([hr]{.smallcaps}): 0.42; *p* \< 0.001\], paralleled by improvements in quality of life[@b6-co16-2-44].

A distinct targeted approach has been used for patients refractory to standard therapy. In a trial using the agent sorafenib (a [tki]{.smallcaps} with inhibitory activity against [vegfr]{.smallcaps}, [pdgfr]{.smallcaps}, Flt-3, and c-Kit) or placebo in such patients, a benefit in time to progression was observed with sorafenib (5.5 months vs. 2.8 months; [hr]{.smallcaps}: 0.44; *p* \< 0.01)[@b7-co16-2-44]. For poor-risk patients, the agent temsirolimus (an inhibitor of the mammalian target of rapamycin) has similarly led to an improvement in [pfs]{.smallcaps}; moreover, temsirolimus is the first of the targeted therapies for m[rcc]{.smallcaps} to also improve [os]{.smallcaps} (7.3 months in patients receiving interferon alfa vs. 10.9 months in patients receiving temsirolimus alone; [hr]{.smallcaps}: 0.73; *p* = 0.008)[@b8-co16-2-44].

Beyond small-molecule [tki]{.smallcaps}s, monoclonal antibody (mAb) therapy for m[rcc]{.smallcaps} has been evaluated in other recent studies. Bevacizumab, a mAb with specificity for [vegfr]{.smallcaps}, was assessed in a phase [iii]{.smallcaps}trial comparing the combination of bevacizumab and interferon alfa with interferon alfa and placebo. In 649 randomized patients, a significant improvement in response rate was observed with the addition of bevacizumab (13% vs. 31%; *p* \< 0.0001), with most of responses being characterized as partial. Median [pfs]{.smallcaps} was improved to 10.2 months from 5.4 months with the addition of bevacizumab ([hr]{.smallcaps}: 0.63; *p* \< 0.0001), and at the time of this (interim) analysis, median [os]{.smallcaps} in the bevacizumab-containing arm had not been reached 9.

2.2 Rationale for the Combination of Bevacizumab and Imatinib
-------------------------------------------------------------

The combination of bevacizumab and imatinib exclusively has not been reported in the existing literature, but a recent trial tested these agents in combination with erlotinib. That study built on data from a randomized phase [ii]{.smallcaps} trial of first-line treatment of m[rcc]{.smallcaps} with bevacizumab and erlotinib as compared with bevacizumab and placebo. In 104 patients, the combination of bevacizumab and erlotinib did not significantly improve [pfs]{.smallcaps} (9.9 months vs. 8.5 months; [hr]{.smallcaps}: 0.86; *p* = 0.58). Interestingly, median [os]{.smallcaps} was not reached in the bevacizumab monotherapy group, but a median [os]{.smallcaps} of 20 months was noted with bevacizumab and erlotinib[@b10-co16-2-44].

A separate phase [i]{.smallcaps}/[ii]{.smallcaps} trial that assessed bevacizumab and erlotinib in combination with imatinib demonstrated a median [pfs]{.smallcaps} of 8.9 months and a median [os]{.smallcaps} of 20 months, thus mirroring the data obtained for single-agent therapy with bevacizumab. However, the addition of imatinib led to a marked increase in reported grades 3 and 4 toxicities, including diarrhea, rash, and fatigue [@b11-co16-2-44]. Thus, although the combination of erlotinib and bevacizumab is well tolerated, efficacy data do not seem to support the addition of the erlotinib. Furthermore, addition of imatinib to this regimen appears to generate unacceptable toxicity.

The case described the present report represents a signal of activity for the combination of bevacizumab and imatinib exclusively. To date, no trials for this specific combination of agents are being conducted, although there are theoretical merits for the combination. Imatinib is an inhibitor of multiple tyrosine kinases, including Abl, Bcr--Abl, [pdgfr]{.smallcaps}, and c-Kit[@b1-co16-2-44]. Among these targets, [pdgfr]{.smallcaps} is of particular relevance to [rcc]{.smallcaps} and is a demonstrated target of sunitinib (together with [vegfr]{.smallcaps} and Flt-3)[@b5-co16-2-44].

A retrospective analysis of 64 patients undergoing partial or radical nephrectomy for [rcc]{.smallcaps} suggested that immunohistochemical staining for [pdgfr]{.smallcaps} is a statistically significant prognostic factor for [os]{.smallcaps} on multivariate analysis [@b12-co16-2-44]. Array studies of tissue suggest that [rcc]{.smallcaps} overproduces [pdgfd]{.smallcaps}, a recently discovered member of the [pdgf]{.smallcaps} family. Transfection of [pdgfd]{.smallcaps} in human [rcc]{.smallcaps} cell lines implanted in mice with severe combined immunodeficiency led to increased cellular proliferation and migration. Inhibition of [pdgfr]{.smallcaps} β activity by imatinib led to a decline in tumour growth, suggesting a therapeutic role of imatinib in [rcc]{.smallcaps} 13.

Imatinib may target the kinase domain of cell surface receptors, but bevacizumab acts in a unique manner---through specific binding to [vegf]{.smallcaps}. *In vitro* and *in vivo* assays have both demonstrated the role of [vegf]{.smallcaps} as a mitogen and angiogenesis inducer; bevacizumab has been shown in experimental models to reduce the growth rate of tumours, with decreased vessel density in bevacizumab-treated specimens [@b14-co16-2-44]. Other studies further suggest that bevacizumab may play a role in tumour vessel normalization, thereby alleviating tumour hypoxia and allowing for improved drug delivery to tumour tissue [@b15-co16-2-44]. The latter hypothesis suggests a mechanism by which imatinib could potentially synergize with bevacizumab.

3. CONCLUSIONS
==============

Results from the phase [i]{.smallcaps}/[ii]{.smallcaps} trial combining bevacizumab, erlotinib, and imatinib should not discourage further exploration of the combination of bevacizumab and imatinib exclusively. The excessive toxicity incurred with the addition of imatinib could be a result of overlapping downstream targets: although imatinib and erlotinib inactivate phosphorylation at distinct [tki]{.smallcaps}s, the result is inhibition of common mitogenic pathways such as the [pi]{.smallcaps}3[k]{.smallcaps}--Akt signalling cascade [@b16-co16-2-44],[@b17-co16-2-44]. Given the exceptional tolerance and prolonged stable disease observed in the present case report, clinical studies of bevacizumab and imatinib should be pursued.

4. RESEARCH SUPPORT AND DISCLAIMERS
===================================

No research funding was applied toward the effort reported here, and this research has not been previously presented.
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